Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634641 | 1.00 | CYP1A2 (0.39) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL30892132 | 1.00 | CYP1A2 (0.39) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL16628563 | 1.00 | CYP1A2 (0.39) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL17936702 | 1.00 | CYP1A2 (0.39) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL18253788 | 0.97 | CYP1A2 (0.39) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL17451907 | 0.93 | CYP1A2 (0.37) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL20089177 | 0.93 | CYP1A2 (0.39) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL21012258 | 0.92 | CYP1A2 (0.36) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL31286508 | 0.91 | CYP1A2 (0.38) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL9890963 | 0.91 | CYP1A2 (0.38) | CYP1A2ERBB2FYNMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055891-B1 | SEMICONDUCTING MATERIAL COMPRISING A PHOSPHINE OXIDE MATRIX AND METAL SALT | NOVALED GMBH (DE) | 2024-10-30 | — | — | EP | disclosed |
| EP-3281238-B1 | SEMICONDUCTING MATERIAL COMPRISING A PHOSPHINE OXIDE MATRIX AND METAL SALT | NOVALED GMBH (DE) | 2024-04-24 | — | — | EP | disclosed |
| US-11309495-B2 | Semiconducting material comprising a phosphine oxide matrix and metal salt | NOVALED GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| EP-2860782-B1 | Semiconducting material comprising a phosphine oxide matrix and metal salt | NOVALED GMBH (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-10026902-B2 | Semiconducting material comprising a phosphine oxide matrix and metal salt | NOVALED GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10026902-B2 | Semiconducting material comprising a phosphine oxide matrix and metal salt | NOVALED GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10026902-B2 | Semiconducting material comprising a phosphine oxide matrix and metal salt | NOVALED GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180114914-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | NOVALED GMBH (DE) | 2018-04-26 | — | — | US | disclosed |
| US-20180114914-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | NOVALED GMBH (DE) | 2018-04-26 | — | — | US | disclosed |
| US-20180114914-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | NOVALED GMBH (DE) | 2018-04-26 | — | — | US | disclosed |
| EP-3281238-A1 | SEMICONDUCTING MATERIAL COMPRISING A PHOSPHINE OXIDE MATRIX AND METAL SALT | Novaled GmbH (DE) | 2018-02-14 | — | — | EP | disclosed |
| EP-3079179-A1 | SEMICONDUCTING MATERIAL COMPRISING A PHOSPHINE OXIDE MATRIX AND METAL SALT | Novaled GmbH (DE) | 2016-10-12 | — | — | EP | disclosed |
| EP-3079179-A1 | SEMICONDUCTING MATERIAL COMPRISING A PHOSPHINE OXIDE MATRIX AND METAL SALT | Novaled GmbH (DE) | 2016-10-12 | — | — | EP | disclosed |
| US-20160211455-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | NOVALED GMBH (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160211455-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | NOVALED GMBH (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160211455-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | NOVALED GMBH (DE) | 2016-07-21 | — | — | US | disclosed |
| EP-2860782-A1 | Semiconducting material comprising a phosphine oxide matrix and metal salt | Novaled GmbH (DE) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11309495-B2 | Semiconducting material comprising a phosphine oxide matrix and metal salt | C1S, C5, SLC26A3 | CYP1A2 3206/4885ERBB2 950/4885FYN 3087/4885 |
| US-10026902-B2 | Semiconducting material comprising a phosphine oxide matrix and metal salt | PSPH, STMN1, STMN2 | CYP1A2 4788/4885ERBB2 3163/4885FYN 1072/4885 |
| US-20180114914-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | C1S, C5, SLC26A3 | CYP1A2 3206/4885ERBB2 950/4885FYN 3087/4885 |
| US-20160211455-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | PSPH, STMN1, STMN2 | CYP1A2 4759/4885ERBB2 3070/4885FYN 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.